DBV Technologies (DBVT) Shares Outstanding (Weighted Average) (2015 - 2026)
DBV Technologies (DBVT) reported Shares Outstanding (Weighted Average) of $428.3 million for Q1 2026, up 317.38% year-over-year from $102.6 million in Q1 2025, and up 400153.11% quarter-over-quarter from $107008.0 in Q4 2025.
DBV Technologies (DBVT) Shares Outstanding (Weighted Average) (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 12 years of Shares Outstanding (Weighted Average) data on file, last reported at $428.3 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $428.3 million, up 317.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $428.3 million (up 317.38% YoY), and the FY2025 annual result was $107008.0, down 99.89% from the prior year.
- Shares Outstanding (Weighted Average) improved to $428.3 million in Q1 2026 per DBVT's latest filing, from $107008.0 in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $428.3 million in Q1 2026 and troughed at $107008.0 in Q4 2025.
- A 5-year average of $63.2 million and a median of $256693.0 in 2022 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) soared 39539.62% in 2024, then tumbled 99.89% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $251693.0 in 2022, then fell by 2.78% to $244693.0 in 2023, then soared by 39539.62% to $97.0 million in 2024, then plunged by 99.89% to $107008.0 in 2025, then soared by 400153.11% to $428.3 million in 2026.
- Business Quant data shows DBVT's Shares Outstanding (Weighted Average) at $428.3 million in Q1 2026, $107008.0 in Q4 2025, and $195508.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | 428.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 428.30 Mn |
| Dec 31, 2025 | 107,008.00 |
| Sep 30, 2025 | 195,508.00 |
| Jun 30, 2025 | 195,508.00 |
| Mar 31, 2025 | 102.62 Mn |
| Dec 31, 2024 | 97.00 Mn |
| Sep 30, 2024 | 244,693.00 |
| Jun 30, 2024 | 244,693.00 |
| Mar 31, 2024 | 96.18 Mn |
| Dec 31, 2023 | 244,693.00 |
| Sep 30, 2023 | 94.80 Mn |
| Jun 30, 2023 | 94.15 Mn |
| Mar 31, 2023 | 93.97 Mn |
| Dec 31, 2022 | 251,693.00 |
| Sep 30, 2022 | 251,693.00 |
| Jun 30, 2022 | 66.05 Mn |
| Mar 31, 2022 | 256,693.00 |
| Dec 31, 2021 | 256,693.00 |
| Sep 30, 2021 | 256,693.00 |
| Mar 31, 2021 | 54.88 Mn |